Rimegepant's indications are expanded, FDA approves it for the prevention of adult migraine

Recently, the U.
S.
Food and Drug Administration (FDA) has expanded the indications of Biohaven's Rimegepant, which can be used to prevent adult migraine.

Yimaitong compiles and organizes, please do not reprint without authorization.

 Last year, Rimegepant became the first calcitonin gene-related peptide (CGRP) receptor antagonist and was approved as a fast-acting orally disintegrating tablet for the acute treatment of migraine in adults with or without aura.

The drug is currently the only migraine drug that can treat acute migraine attacks and help prevent future migraine attacks.

 The new indication allows the use of rimegepant for preventive treatment of adults with episodic migraine (the number of migraine days per month> 15 days).

A maximum of 18 doses can be used per month, including acute and preventive treatments.

 In the Phase 2/3 study, oral rimegepant was superior to placebo in reducing the number of migraine days per month.

About half of the adults who took the drug reduced the number of days of moderate-to-severe migraine each month by 50% or more.

The most common side effects were nausea (2.
7%) and stomach pain or indigestion (2.
4%).

 Peter J.
Goadsby, a professor of neurology from the University of California, Los Angeles, said that the FDA approved rimegepant for the preventive treatment and acute treatment indications of migraine, which occurred during the course of migraine treatment during his 40 years in headache medicine.
One of the most groundbreaking things.

Allowing patients to use one drug to prevent and treat migraine may change the treatment model for millions of migraine patients.

 Yimaitong is translated from: FDA Expands Rimegepant Indication to Include Migraine Prevention-Medscape-May 28, 2021.